Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Sonnet BioTherapeutics Holdings, Inc. (SONN)

2.94   -0.08 (-2.65%) 09-26 16:00
Open: 3 Pre. Close: 3.02
High: 3.05 Low: 2.8804
Volume: 42,076 Market Cap: 5(M)

Technical analysis

as of: 2023-09-26 3:22:30 PM
Short-term rate:       
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Mid-term rate:       
Target: Six months: 6.04     One year: 7.7
Support: Support1: 2.88    Support2: 2.39
Resistance: Resistance1: 5.17    Resistance2: 6.59
Pivot: 3.56
Moving Average: MA(5): 3.12     MA(20): 3.96
MA(100): 8.06     MA(250): 16.1
MACD: MACD(12,26): -1     Signal(9): -1.1
Stochastic oscillator: %K(14,3): 5.1     %D(3): 3.7
RSI: RSI(14): 22.5
52-week: High: 66  Low: 2.88
Average Vol(K): 3-Month: 80 (K)  10-Days: 50 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ SONN ] has closed above bottom band by 10.7%. Bollinger Bands are 71.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 3.1 - 3.13 3.13 - 3.14
Low: 2.87 - 2.9 2.9 - 2.92
Close: 2.98 - 3.02 3.02 - 3.05

Company Description

Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy. It has a license agreement with New Life Therapeutics PTE, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin 6. Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey.

Headline News

Wed, 20 Sep 2023
Raymond James Analyst Upgrades Delek US Hldgs Price Target to 34 - Best Stocks

Tue, 19 Sep 2023
Sonnet BioTherapeutics Regains Nasdaq Minimum Bid Price ... - BioSpace

Fri, 01 Sep 2023
Sonnet BioTherapeutics Implements Reverse Stock Split - Nasdaq

Fri, 01 Sep 2023
Sonnet BioTherapeutics Holdings, Inc. (SONN) has risen 2220.00% Friday In Premarket Trading - InvestorsObserver

Thu, 31 Aug 2023
U.S. shares mixed at close of trade; Dow Jones Industrial Average ... - Canada

Thu, 31 Aug 2023
Why Sonnet BioTherapeutics Stock (SONN) Is Getting Obliterated - Sonnet BioTherapeutics (NASDAQ:SONN) - Benzinga

Financial Analysis

Price to Book Value: Underperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. -15 (M)
Shares Float 0 (M)
% Held by Insiders 1.75e+006 (%)
% Held by Institutions 1.48e+006 (%)
Shares Short 0 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -2.109e+007
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -49.75
Profit Margin (%) 0
Operating Margin (%) -13
Return on Assets (ttm) 23.1
Return on Equity (ttm) -161
Qtrly Rev. Growth 80.2
Gross Profit (p.s.) -154.5
Sales Per Share -953.88
EBITDA (p.s.) -5.2725e+007
Qtrly Earnings Growth -2.256e+007
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value -0.07
Price to Sales -0.01
Price to Cash Flow 0

Stock Dividends

Dividend 33620
Forward Dividend 16210
Dividend Yield 1124410%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.